DB16439InvestigationalVaccines
EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus . It is currently... It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575).
- Code names
- EpiVacCorona
What you can answer from here — as of January 16, 2021
Which companies are running trials of EpiVacCorona, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account